Can Treg therapy prevent GVHD?
KV Komanduri, RE Champlin - Blood, The Journal of the …, 2011 - ashpublications.org
KV Komanduri, RE Champlin
Blood, The Journal of the American Society of Hematology, 2011•ashpublications.orgIn this issue of Blood, Brunstein and colleagues report the results of the first study to test the
safety of human umbilical cord blood–derived regulatory T cells (Tregs), an approach
designed to decrease graft-versus-host disease. 1 Transplanters, like Sisyphus of myth,
have struggled mightily with trials of pharmacologic immunosuppressive drugs—we roll the
rock up the mountain, only to see it roll back, leaving us where we began. This struggle has
now led us to seek cellular therapies as a promising alternative.
safety of human umbilical cord blood–derived regulatory T cells (Tregs), an approach
designed to decrease graft-versus-host disease. 1 Transplanters, like Sisyphus of myth,
have struggled mightily with trials of pharmacologic immunosuppressive drugs—we roll the
rock up the mountain, only to see it roll back, leaving us where we began. This struggle has
now led us to seek cellular therapies as a promising alternative.
In this issue of Blood, Brunstein and colleagues report the results of the first study to test the safety of human umbilical cord blood–derived regulatory T cells (Tregs), an approach designed to decrease graft-versus-host disease. 1 Transplanters, like Sisyphus of myth, have struggled mightily with trials of pharmacologic immunosuppressive drugs—we roll the rock up the mountain, only to see it roll back, leaving us where we began. This struggle has now led us to seek cellular therapies as a promising alternative.
ashpublications.org